In a news release out this morning, Biomoda, Inc. (OTCBB: BMOD) announced that they have engaged Dr. Thomas Bauer, a renowned researcher in the field of cancer diagnostics, to read the follow-up CT scans and other data on study participants as part of the longitudinal component of the research of the Company’s ongoing Phase II clinical trial for the early detection of lung cancer.
Dr. Bauer brings a wealth of experience to the Biomoda team with a long history in the medical/cancer diagnostic industry including posts as chief of thoracic surgery at the Helen F. Graham Cancer Center, Christiana Care Health System, in Delaware as well as clinical assistant professor of surgery at Jefferson Medical College and adjunct assistant professor of biological sciences at the University of Delaware. Dr Bauer has led several lung and esophageal cancer studies and heads up Christiana’s participation in the International Early Lung Cancer Action Program (I-ELCAP).
Biomoda, Inc. has announced recently that the Company’s Phase II clinical trial, in which they have enrolled 500 military veterans for the early screening and detection of lung cancer is proceeding on schedule with over 130 participants screened to date. The Company’s core technology, is based on a group of patents held by the Company for a molecular biomarker called TCPP, which preferentially binds with cancer cells and fluoresces red under ultraviolet light. Biomoda’s screening protocal is non-invasive, cost effective and looks to be highly reliable in the diagnosis of lung cancer at an earlier stage that current screening protocals such as MRI and CT/PET scans, which could make it a highly valuable low cost, early screening tool for determining cancer in asymptomatic individuals.
To read today’s full press release click here